natgillin/translations-raw huggingface dataset:
When used with other medicines for diabetes, the recommended dose is 1.5 mg once a week. 
Ob uporabi skupaj z drugimi zdravili za zdravljenje sladkorne bolezni je priporočeni odmerek zdravila 1,5 mg enkrat na teden.
Do not recycle the filled sharps container. 
• Polnega vsebnika za ostre odpadke ne reciklirajte.
Check 
Preverite
If you are taking a sulphonylurea or insulin, the dose may need to be lowered while you use dulaglutide. 
Če jemljete sulfonilsečnino ali insulin, bo morda treba odmerek zmanjšati za čas, ko uporabljate dulaglutid.
Effects of overdose with dulaglutide in clinical studies have included gastrointestinal disorders and hypoglycaemia. 
Učinki prevelikega odmerjanja so v kliničnih študijah z dulaglutidom vključevali gastrointestinalne motnje in hipoglikemijo.
These changes were not clinically relevant; therefore no dose adjustment of lisinopril or metoprolol is necessary when administered with dulaglutide. 
Te spremembe se niso štele za klinično pomembne, zato prilagoditev odmerka lisinoprila ali metoprolola, če je to zdravilo dano sočasno z dulaglutidom, ni potrebna.
Because Trulicity can slow stomach emptying which could affect other medicines, tell your doctor, pharmacist or nurse if you are using, have recently used or might use any other medicine. 
Druga zdravila in zdravilo Trulicity Ker lahko zdravilo Trulicity zmanjša praznenje želodca, kar lahko vpliva na druga zdravila, obvestite zdravnika, farmacevta ali medicinsko sestro, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
Dulaglutide exhibits several antihyperglycaemic actions of GLP-1. 
Dulaglutid kaže več antihiperglikemičnih učinkov GLP-1.
Dulaglutide is presumed to be degraded into its component amino acids by general protein catabolism pathways. 
Domneva se, da se dulaglutid razgrajuje v svoje sestavne dele − aminokisline prek splošnih poti katabolizma beljakovin.
Within each incidence grouping, adverse reactions are presented in order of decreasing frequency. 
V okviru razvrstitev po incidenci so neželeni učinki navedeni po padajoči pogostnosti.
After Week 1, patients were up-titrated to 1.2 mg/day and then at Week 2 to 1.8 mg/day. 
Po 1. tednu so jim odmerek titrirali do 1,2 mg/dan, v 2. tednu pa do 1,8 mg/dan.
• If you have vision problems, DO NOT use your pen without help from a person trained to use the Trulicity pen. 
• Če imate težave z vidom, NE uporabljajte svojega peresnika brez pomoči osebe, ki je usposobljena za uporabo peresnika Trulicity.
Statistically significant reductions in Cmax of 26 % and 13 % and delays in tmax of 2 and 0.30 hours were observed for norelgestromin and ethinyl estradiol, respectively. 
Opazili pa so statistično pomembna znižanja Cmax za 26 % in 13 % ter zakasnitvi tmax za 2 in 0,30 ure za norelgestromin in etinilestradiol.
The improvement in fasting glucose was sustained through the longest study duration of 104 weeks. 
Izboljšanje glukoze na tešče se je ohranilo vse do 104. tedna, kolikor je trajala najdaljša študija.
Potentially immune-mediated injection site adverse events (e.g., rash, erythema) were reported in 0.7 % of patients and were usually mild. 
O potencialno imunskih reakcijah na mestu injiciranja (npr. izpuščaj, eritem) so poročali pri 0,7 % bolnikov in so bile običajno blage.
To optimise the insulin glargine dose, both groups were titrated to a target fasting serum glucose of <5.6 mmol/L. 
Za optimizacijo odmerka insulina glargina sta bili obe skupini titrirani na ciljno serumsko glukozo na tešče < 5,6 mmol/l.
In clinical studies, treatment with dulaglutide was associated with a 1.6 % incidence of treatment emergent dulaglutide anti-drug antibodies, indicating that the structural modifications in the GLP-1 and modified IgG4 parts of the dulaglutide molecule, together with high homology with native GLP-1 and native IgG4, minimise the risk of immune response against dulaglutide. 
V kliničnih študijah je bilo zdravljenje z dulaglutidom povezano z 1,6% incidenco protiteles proti dulaglutidu, nastalih med zdravljenjem, kar kaže na to, da strukturne modifikacije v GLP-1 in modificiranih delih IgG4 molekule dulaglutida skupaj z visoko homolognostjo z naravnim GLP-1 in naravnim IgG4 zmanjšujejo tveganje za odziv imunskega sistema na dulaglutid.
Table 1: The frequency of adverse reactions of dulaglutide 
Preglednica 1: Pogostnost neželenih učinkov dulaglutida
If pancreatitis is confirmed, dulaglutide should not be restarted. 
Če je pankreatitis potrjen, se zdravljenja z dulaglutidom ne sme znova uvesti.
In all studies, dulaglutide produced clinically significant improvements in glycaemic control as measured by glycosylated haemoglobin A1c (HbA1c). 
V vseh študijah je dulaglutid povzročil klinično pomembna izboljšanja v glikemični urejenosti, merjeni z glikoziliranim hemoglobinom A1c (HbA1c).
No cases of severe hypoglycaemia were observed for Trulicity or placebo. 
Primerov hude hipoglikemije pri zdravilu Trulicity ali pri placebu niso opazili.
At baseline, overall mean eGFR was 38 mL/min/1.73 m2, 30% of patients had eGFR < 30 mL/min/1.73 m2. 
V izhodišču je skupni mediani eGFR znašal 38 ml/min/1,73 m2, 30 % bolnikov pa je imelo eGFR < 30 ml/min/1,73 m2.
If a dose is missed, it should be administered as soon as possible if there are at least 3 days (72 hours) until the next scheduled dose. 
V primeru zamujenega odmerka je treba odmerek dati čimprej, če manjkajo vsaj 3 dnevi (72 ur) do naslednjega predpisanega odmerka.
Kaplan-Meier plot of time to first occurrence of the composite outcome: CV death, non-fatal myocardial infarction or non-fatal stroke, in the dulaglutide long-term cardiovascular outcome study 
Kaplan-Meierjeva krivulja časa do prvega pojava sestavljenega izida: KV-smrti, miokardnega infarkta brez smrtnega izida ali možganske kapi brez smrtnega izida, v dolgoročni študiji kardiovaskularnega izida z dulaglutidom
If you use Trulicity in combination with a sulphonylurea or insulin, low blood sugar (hypoglycaemia) may occur which may reduce your ability to concentrate. 
Če uporabljate zdravilo Trulicity v kombinaciji s sulfonilsečnino ali insulinom, lahko pride do nizkega krvnega sladkorja (hipoglikemija), ki lahko zmanjša vašo sposobnost koncentracije.
If you use more Trulicity than you should 
Če ste uporabili večji odmerek zdravila Trulicity, kot bi smeli
In clinical trials, acute pancreatitis has been reported in association with dulaglutide (see section 4.8). 
kliničnih preskušanjih so o akutnem pankreatitisu poročali v povezavi z dulaglutidom (glejte poglavje 4.8).
In the rat, there was no direct effect on mating or fertility following treatment with dulaglutide (see section 5.3). 
Pri podganah po zdravljenju z dulaglutidom ni bilo neposrednega učinka na parjenje ali plodnost (glejte poglavje 5.3).
Treatment with dulaglutide provided reductions in systolic blood pressure (SBP) (-2.8 mmHg difference compared to placebo) at 16 weeks. 
Zdravljenje z dulaglutidom je povzročilo znižanja sistolnega krvnega tlaka (razlika -2,8 mmHg v primerjavi s placebom) po 16 tednih.
• If you have vision problems, DO NOT use your syringe without help from a person trained to use the Trulicity syringe. 
• Če imate težave z vidom, NE uporabljajte svoje injekcijske brizge brez pomoči osebe, ki je usposobljena za uporabo injekcijske brizge Trulicity.
Hypersensitivity Anaphylactic reaction# 
Bolezni imunskega sistema preobčutljivost anafilaktična reakcija#
The risk of hypoglycaemia may be lowered by a reduction in the dose of sulphonylurea or insulin (see sections 4.2 and 4.8). 
Tveganje hipoglikemije je mogoče zmanjšati z znižanjem odmerka sulfonilsečnine ali insulina (glejte poglavji 4.2 in 4.8).
Trulicity is injected under the skin (subcutaneous injection) of your stomach area (abdomen) or upper leg (thigh). 
Zdravilo Trulicity se injicira pod kožo (subkutana injekcija) vašega trebušnega predela (trebuh/abdomen) ali zgornjega dela noge (stegno).
Coadministration of dulaglutide with an oral contraceptive (norgestimate 0.18 mg/ethinyl estradiol 0.025 mg) did not affect the overall exposure to norelgestromin and ethinyl estradiol. 
Sočasna aplikacija dulaglutida s peroralnim kontraceptivom (norgestimat 0,18 mg/etinilestradiol 0,025 mg) ni vplivala na celokupno izpostavljenost norelgestrominu in etinilestradiolu.
Decreased appetite, dyspepsia, constipation, flatulence, abdominal distention, gastroesophageal reflux disease, eructation 
zmanjšan apetit, dispepsija, zaprtje, flatulenca, trebušna distenzija, gastroezofagealna refluksna bolezen, spahovanje akutni pankreatitis nemehanska obstrukcija črevesja
• For complete information about proper storage, read the Information for the patient. 
• Za celotne informacije o primernem shranjevanju preberite Navodilo za uporabo.
In the clinical pharmacology studies described below, dulaglutide did not affect the absorption of the orally administered medications tested to any clinically relevant degree. 
V klinično farmakoloških študijah opisanih spodaj, dulaglutid ni vplival na absorpcijo zdravil za peroralno uporabo, testiranih v vseh klinično pomembnih stopnjah.
Of these, 1,206 were ≥ 65 years of which 119 were ≥ 75 years. 
V teh študijah je bilo 1206 bolnikov starih ≥ 65 let, od teh pa je bilo 119 bolnikov starih ≥ 75 let.
Dulaglutide should not be used during breast-feeding. 
Dulaglutida se med dojenjem ne sme uporabljati.
For potentially vulnerable populations 0.75 mg once weekly can be considered as a starting dose. 
Za potencialno ranljive skupine bolnikov se lahko odmerek 0,75 mg upošteva kot začetni odmerek.
In clinical pharmacology studies conducted in patients with type 2 diabetes mellitus up to 6 weeks, the majority of gastrointestinal events were reported during the first 2-3 days after the initial dose and declined with subsequent doses. 
V kliničnih farmakoloških študijah, ki so jih opravili pri bolnikih s sladkorno boleznijo tipa 2 v obdobju do 6 tednov, so o večini gastrointestinalnih neželenih učinkov poročali v prvih 2-3 dneh po začetnem odmerku, po nadaljnjem odmerjanju pa je poročanje o neželenih učinkih upadalo.
Pharmacotherapeutic group: Drugs used in diabetes, blood glucose lowering drugs, excl. insulins, ATC code: A10BJ05 
Farmakoterapevtska skupina: zdravila za zdravljenje diabetesa, antidiabetiki razen insulinov, oznaka ATC: A10BJ05.
If you forget to inject a dose, and if there are at least 3 days before your next dose is due, then inject your dose as soon as possible. 
Če si pozabite injicirati odmerek, in ostanejo vsaj še 3 dnevi do naslednjega predpisanega odmerka, si svoj odmerek injicirajte takoj, ko je to mogoče.
Leave the Base Cap on until you are ready to inject. 
Pokrovčka z dna ne odstranjujte, dokler niste pripravljeni na injiciranje.
Treatment with dulaglutide resulted in significant reductions in mean post prandial glucose from baseline (changes from baseline to primary time point -1.95 mmol/L to -4.23 mmol/L). 
Zdravljenje z dulaglutidom je povzročilo značilna znižanja povprečnih koncentracij postprandialne glukoze od izhodišča (spremembe od izhodišča so prve časovne točke -1,95 mmol/l do -4,23 mmol/l).
In the absence of other signs and symptoms of acute pancreatitis, elevations in pancreatic enzymes alone are not predictive of acute pancreatitis (see section 4.8). 
Če ni drugih znakov in simptomov akutnega pankreatitisa, sama zvišanja ravni encimov trebušne slinavke ne napovedujejo akutnega pankreatitisa (glejte poglavje 4.8).
Rare: may affect up to 1 in 1,000 people - Severe allergic reactions (anaphylactic reactions, angioedema). 
Redki: pojavijo se lahko pri največ 1 od 1000 bolnikov - hude alergične reakcije (anafilaktične reakcije, angioedem).
Trulicity is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise 
Zdravilo Trulicity je indicirano za zdravljenje odraslih z nezadostno urejeno sladkorno boleznijo tipa 2 kot dopolnilo k dieti in telesni vadbi:
After coadministration with up to 3 mg of dulaglutide at steady state, there were no statistically significant differences on AUC(0-12), Cmax or tmax of paracetamol. 
Po sočasnem dajanju dulaglutida do 3 mg v stanju dinamičnega ravnovesja ni bilo klinično pomembnih razlik v AUC(0-12), Cmax ali tmax paracetamola.
Dulaglutide suppresses glucagon secretion which is known to be inappropriately elevated in patients with type 2 diabetes. 
Dulaglutid zavira izločanje glukagona, za katerega je znano, da je pri bolnikih s sladkorno boleznijo tipa 2 neprimerno povišan.
The primary endpoint was the time from randomisation to first occurrence of any major adverse cardiovascular events (MACE): CV death, non-fatal myocardial infarction, or non-fatal stroke. 
Primarni opazovani dogodek je bil čas od randomizacije do prvega pojava katerega koli večjega kardiovaskularnega neželenega učinka (MACE: KV-smrti, miokardnega infarkta brez smrtnega izida ali možganske kapi brez smrtnega izida.
The results showed that there was no increase in CV risk with dulaglutide compared with control therapies (HR: 0.57; CI: [0.30, 1.10]). 
Rezultati kažejo, da ni bilo povečanja kardiovaskularnega tveganja pri dulaglutidu v primerjavi s kontrolnimi zdravljenji (srčni utrip: 0,57; interval zaupanja: [0,30, 1,10]).
Exposures after subcutaneous administration of single dulaglutide (1.5 mg) doses in the abdomen, thigh, or upper arm were comparable. 
Izpostavljenosti po subkutani aplikaciji enkratnih odmerkov dulaglutida (1,5 mg) v trebuh, stegno ali nadlaket, so bile primerljive.
How to use Trulicity 
Kako uporabljati zdravilo Trulicity
Trulicity 1.5 mg was associated with sustained weight reduction over the duration of studies (from baseline to final time point -0.35 kg to -2.90 kg). 
Zdravilo Trulicity 1,5 mg je bilo povezano s trajnim zmanjšanjem telesne mase v času študij (od izhodišča do končne časovne točke 0.35 kg do -2.90 kg).
There was no difference in diastolic blood pressure (DBP). 
Pri diastolnem krvnem tlaku ni bilo razlik.
Also contact your local Lilly office listed in the Information for the patient for further instructions. 
Prav tako se za nadaljnja navodila obrnite na lokalno podružnico družbe Lilly, navedeno v navodilu za uporabo.
Combination therapy with prandial insulin with or without metformin In this study, patients on 1 or 2 insulin injections per day prior to study entry, discontinued their prestudy insulin regimen and were randomised to dulaglutide once weekly or insulin glargine once daily, both in combination with prandial insulin lispro three times daily, with or without metformin. 
Kombinirano zdravljenje s prandialnim insulinom z ali brez metformina V tej študiji so bolniki, ki so pred vstopom v študijo dobivali 1 ali 2 injekciji insulina na dan, prekinili svoj predštudijski insulinski režim in so bili randomizirani v skupino z dulaglutidom enkrat na teden ali v skupino z insulinom glarginom enkrat na dan, obakrat v kombinaciji s prandialnim insulinom lispro trikrat na dan, z ali brez metformina.
In certain situations, for example if you are 75 years or older, your doctor may recommend a starting dose of 0.75 mg once a week. 
Če ste starejši od 75 let vam lahko vaš zdravnik priporoči začetni odmerek 0,75 mg enkrat na teden.
Cholelithiasis, cholecystitis 
žolčnika in žolčevodov holelitiaza, holecistitis
Pharmacokinetic analyses have demonstrated a statistically significant inverse relationship between body weight or body mass index (BMI) and dulaglutide exposure, although there was no clinically relevant impact of weight or BMI on glycaemic control. 
Farmakokinetične analize so pokazale statistično značilno obratno sorazmerje med telesno maso ali indeksom telesne mase (ITM) in izpostavljenostjo dulaglutidu, čeprav ni bilo klinično pomembnega vpliva mase ali ITM na glikemično urejenost.
The time of international normalised ratio response (tINRmax) was delayed by 6 hours, consistent with delays in tmax of approximately 4 and 6 hours for S- and R-warfarin, respectively. 
Čas največjega mednarodno umerjenega opaženega odziva INR (tINRmax) se je zakasnil za približno 6 ur, kar je bilo skladno z zakasnitvami tmax za približno 4 in 6 ur za S- in R-varfarin.
Hypoglycaemia* (when used as monotherapy or in combination with metformin plus pioglitazone) 
hipoglikemija* (ob uporabi v monoterapiji ali v kombinaciji z metforminom in pioglitazonom)
28 weeks 
28 tednov
Changes in body weight with Trulicity 0.75 mg ranged from 0.86 kg to -2.63 kg. 
Spremembe v telesni masi za zdravilo Trulicity 0,75 mg so obsegale od 0,86 kg do -2,63 kg.
At the end of the 28 week treatment period the dose was 65 units/day and 51 units/day, for patients receiving placebo and Trulicity 1.5 mg, respectively. 
Ob koncu 28-tedenskega obdobja zdravljenja je bil odmerek 65 enot/dan za bolnike, ki so prejemali placebo, oziroma 51 enot/dan za bolnike, ki so prejemali zdravilo Trulicity 1,5 mg.
Many of the reported adverse renal events occurred in patients who had experienced nausea, vomiting, diarrhoea, or dehydration. 
Številni neželeni učinki na ledvice, o katerih so poročali, so se pojavili pri bolnikih, pri katerih se je pojavila slabost, bruhanje, driska ali dehidracija.
These effects were not considered to be clinically relevant. 
Ti učinki se niso upoštevali za klinično pomembne.
If you use more Trulicity than you should talk to your doctor immediately. 
Če ste uporabili večji odmerek zdravila Trulicity, kot bi smeli, morate takoj obvestiti zdravnika.
Too much Trulicity may make your blood sugar too low (hypoglycaemia) and can make you feel sick or be sick. 
Zaradi prevelike količine zdravila Trulicity lahko vaš krvni sladkor pade prenizko (hipoglikemija), zaradi česar se lahko slabo počutite oz. vam postane slabo.
If the syringe has been frozen, DO NOT USE. 
Če je bila injekcijska brizga zamrznjena, JE NE UPORABITE.
Through the full study duration (up to 104 weeks), the incidence of discontinuation due to adverse events was 5.1% (0.75 mg) and 8.4 % (1.5 mg) for dulaglutide. 
V času trajanja celotne študije (do 104 tedne) je bila incidenca prekinitev zaradi neželenih dogodkov 5,1 % (0,75 mg) in 8,4 % (1,5 mg) za dulaglutid.
Especially tell your doctor: - if you are using other medicines that lower the amount of sugar in your blood, such as insulin or a medicine containing sulphonylurea. 
- če jemljete druga zdravila, ki zmanjšujejo količino sladkorja v vaši krvi, npr. insulin ali zdravilo, ki vsebuje sulfonilsečnino.
In-use: Trulicity may be stored unrefrigerated for up to 14 days at a temperature not above 30ºC. 
Začasno shranjevanje: Zdravilo Trulicity lahko do 14 dni shranjujete zunaj hladilnika, pri temperaturi, ki ne presega 30 ºC.
The safety and efficacy of dulaglutide as add-on to a sulphonylurea was investigated in a placebo controlled study of 24 weeks duration. 
Varnost in učinkovitost dulaglutida kot dodatka sulfonilsečnini so preučevali v študiji, nadzorovani s placebom, ki je trajala 24 tednov.
+ Patients randomised to liraglutide were initiated at a dose of 0.6 mg/day. 
+ Bolniki, randomizirani v skupino z liraglutidom so zdravljenje začeli z odmerkom 0,6 mg/dan.
The other ingredients are sodium citrate (see section 2 under ‘Trulicity contains sodium citrate' for further information); citric acid, anhydrous; mannitol; polysorbate 80 and water for injections. 
Druge sestavine zdravila so natrijev citrat (za več informacij glejte poglavje 2, »Zdravilo Trulicity vsebuje natrijev citrat«), brezvodna citronska kislina, manitol, polisorbat 80 in voda za injekcije.
These changes are not clinically relevant. 
Te spremembe niso klinično pomembne.
Do not stop using Trulicity without talking with your doctor. 
Ne prenehajte uporabljati zdravila Trulicity, ne da bi se prej posvetovali z zdravnikom.
How can I tell if I have completed my injection? 
Kako vem, da je injiciranje končano?
The pharmacokinetics of dulaglutide were evaluated in a clinical pharmacology study and were generally similar between healthy subjects and patients with mild to severe renal impairment (CrCl < 30 ml/min), including end stage renal disease (requiring dialysis). 
Farmakokinetika dulaglutida je bila ocenjena v študiji klinične farmakologije in je bila na splošno podobna med zdravimi preiskovanci in bolniki z blago do hudo okvaro delovanja ledvic (CrCl < 30 ml/min), vključno s končno ledvično odpovedjo (bolniki na dializi).
26 weeks 
26 tednov
The pharmacokinetics of dulaglutide were evaluated in a clinical pharmacology study, where subjects with hepatic impairment had statistically significant decreases in dulaglutide exposure of up to 30 % to 33 % for mean Cmax and AUC, respectively, compared to healthy controls. 
Farmakokinetika dulaglutida je bila ocenjena v študiji klinične farmakologije, kjer so imeli preiskovanci z okvarjenim delovanjem jeter statistično značilna zmanjšanja izpostavljenosti dulaglutidu od 30 % do 33 % za povprečne vrednosti Cmax in AUC v primerjavi z zdravimi preiskovanci.
The initial insulin glargine doses in patients with HbA1c <8.0% were reduced by 20%. 
Izhodiščni odmerki insulina glargina pri bolnikih s HbA1c < 8,0% so bili zmanjšani za 20
- Inflamed pancreas (acute pancreatitis) which could cause severe pain in the stomach and back which does not go away. 
- Vnetje trebušne slinovke (akutni pankreatitis) kar lahko povzroča hudo bolečino v trebuhu in v hrbtu, ki ne preneha.
When Trulicity is added to existing metformin and/or pioglitazone therapy, the current dose of metformin and/or pioglitazone can be continued. 
Če je zdravilo Trulicity dodano obstoječemu zdravljenju z metforminom in/ali pioglitazonom, je mogoče nadaljevati s trenutnim odmerkom metformina in/ali pioglitazona.
A pharmacodynamic study with dulaglutide demonstrated, in patients with type 2 diabetes, a restoration of first phase insulin secretion to a level that exceeded levels observed in healthy subjects on placebo, and improved second phase insulin secretion in response to an intravenous bolus of glucose. 
Farmakodinamična študija z dulaglutidom je pri bolnikih s sladkorno boleznijo tipa 2 dokazala obnovo prvostopenjskega izločanja insulina na raven, ki je presegla ravni, opažene pri zdravih preiskovancih, ki so prejemali placebo, ter izboljšala drugostopenjsko izločanje insulina kot odgovor na intravenski bolus glukoze.
- if you are using insulin, your doctor will tell you how to reduce the dose of insulin and will recommend you to monitor your blood sugar more frequently, in order to avoid hyperglycaemia (high blood sugar) and diabetic ketoacidosis (a complication of diabetes that occurs when the body is unable to break down glucose because there is not enough insulin). 
- če uporabljate insulin; zdravnik vam bo povedal, kako zmanjšate odmerek insulina, in vam priporočil pogostejše spremljanje sladkorja v krvi, da s tem preprečite pojav hiperglikemije (visoka raven sladkorja v krvi) in diabetične ketoacidoze (zaplet pri sladkorni bolezni, ki nastopi,
≥ 1/1,000 to < 1/100; rare: ≥ 1/10,000 to < 1/1,000; very rare: < 1/10,000 and not known: cannot be estimated from available data). 
Neželeni učinki so navedeni v Preglednici 1 po organskih sistemih, kot je priporočeno po MedDRA, in razvrščeni po padajoči incidenci (zelo pogosti: ≥ 1/10; pogosti: ≥ 1/100 do < 1/10; občasni: ≥ 1/1.000 do < 1/100; redki: ≥ 1/10.000 do < 1/1.000; zelo redki: < 1/10.000 in neznano: pogostnosti ni mogoče oceniti na podlagi razpoložljivih podatkov).
When a single dose of dulaglutide and metoprolol were coadministered, the AUC and Cmax of metoprolol increased by19 % and 32 %, respectively. 
Ko so sočasno aplicirali po en odmerek dulaglutida in metoprolola, sta se AUC in Cmax metoprolola povečala za 19 % in 32 %.
The recommended dose is 1.5 mg once weekly. 
Priporočeni odmerek je 1,5 mg enkrat na teden.
The most frequently reported adverse reactions in clinical trials were gastrointestinal, including nausea, vomiting and diarrhoea. 
Neželeni učinki, o katerih so v kliničnih preskušanjih poročali najpogosteje, so bili gastrointestinalni, vključno s slabostjo, bruhanjem in drisko.